LT3062824T - Telomerazė, koduojanti dnr vakciną - Google Patents

Telomerazė, koduojanti dnr vakciną

Info

Publication number
LT3062824T
LT3062824T LTEP14790592.1T LT14790592T LT3062824T LT 3062824 T LT3062824 T LT 3062824T LT 14790592 T LT14790592 T LT 14790592T LT 3062824 T LT3062824 T LT 3062824T
Authority
LT
Lithuania
Prior art keywords
dna vaccine
telomerase
coding
telomerase coding
vaccine
Prior art date
Application number
LTEP14790592.1T
Other languages
English (en)
Inventor
Pierre Langlade Demoyen
Simon Wain-Hobson
Thierry Huet
Christelle LIARD
Elodie PLIQUET
Original Assignee
Invectys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invectys filed Critical Invectys
Publication of LT3062824T publication Critical patent/LT3062824T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001157Telomerase or TERT [telomerase reverse transcriptase]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/1276RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/35Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • C12Y207/07049RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
LTEP14790592.1T 2013-10-28 2014-10-28 Telomerazė, koduojanti dnr vakciną LT3062824T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13190547 2013-10-28
PCT/EP2014/073164 WO2015063117A1 (en) 2013-10-28 2014-10-28 A telomerase encoding dna vaccine

Publications (1)

Publication Number Publication Date
LT3062824T true LT3062824T (lt) 2020-05-25

Family

ID=49515221

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14790592.1T LT3062824T (lt) 2013-10-28 2014-10-28 Telomerazė, koduojanti dnr vakciną

Country Status (25)

Country Link
US (2) US10183065B2 (lt)
EP (2) EP3062824B1 (lt)
JP (1) JP6545162B2 (lt)
KR (1) KR102252756B1 (lt)
CN (1) CN106061509B (lt)
AU (1) AU2014343813B2 (lt)
BR (1) BR112016009002B1 (lt)
CA (1) CA2927702C (lt)
CY (1) CY1122839T1 (lt)
DK (1) DK3062824T3 (lt)
EA (1) EA034928B1 (lt)
ES (1) ES2771862T3 (lt)
HR (1) HRP20200211T1 (lt)
HU (1) HUE047898T2 (lt)
IL (1) IL245186B (lt)
LT (1) LT3062824T (lt)
MX (1) MX372778B (lt)
NZ (1) NZ719098A (lt)
PL (1) PL3062824T3 (lt)
PT (1) PT3062824T (lt)
RS (1) RS60232B1 (lt)
SG (1) SG11201603118TA (lt)
SI (1) SI3062824T1 (lt)
WO (1) WO2015063117A1 (lt)
ZA (1) ZA201603452B (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2771862T3 (es) 2013-10-28 2020-07-07 Invectys Una vacuna de ADN que codifica telomerasa
PT3359183T (pt) * 2015-10-06 2020-08-13 Invectys Construções de poliepítopo para utilização em imunoterapia
EP3622078A1 (en) 2017-05-09 2020-03-18 Invectys Recombinant measles vaccine expressing htert
CN120137971A (zh) * 2019-07-25 2025-06-13 诺华股份有限公司 可调节的表达系统
WO2021163556A1 (en) * 2020-02-12 2021-08-19 The Children's Hospital Of Philadelphia Compositions and methods for inducible alternative splicing regulation of gene expression
US20230233656A1 (en) * 2020-06-26 2023-07-27 National Breast Cancer Coalition Breast Cancer Vaccine
EP4175666A1 (en) * 2020-07-03 2023-05-10 Statens Serum Institut A dna plasmid sars-coronavirus-2/covid-19 vaccine
CN116870195A (zh) * 2020-09-22 2023-10-13 浙江愈方生物科技有限公司 一种灭活性端粒酶、具有其的腺病毒和人造mRNA及应用
WO2022236301A1 (en) * 2021-05-05 2022-11-10 Inovio Pharmaceuticals Inc. Vaccines against coronavirus and methods of use
WO2024126758A2 (en) * 2022-12-14 2024-06-20 Ultimovacs Ab A nucleic acid molecule and a chimeric polypeptide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2075196T3 (es) 1989-02-17 1995-10-01 Chiron Mimotopes Pty Ltd Metodo para el uso y la sintesis de peptidos.
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
EP0841396B2 (en) 1996-10-01 2012-04-11 Geron Corporation Human telomerase catalytic subunit
WO2003038047A2 (en) 2001-10-29 2003-05-08 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
US20040106128A1 (en) 2002-06-27 2004-06-03 Majumdar Anish Sen Cancer vaccines containing xenogeneic epitopes of telomerase reverse transcriptase
EP1748067A1 (en) * 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
US20090162405A1 (en) 2006-12-14 2009-06-25 Yong Qian Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells
ATE534661T1 (de) * 2006-10-12 2011-12-15 Angeletti P Ist Richerche Bio Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davon
US8686127B2 (en) * 2008-04-11 2014-04-01 Lsip, Llc Apoptosis inducer
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
JP2012039877A (ja) 2009-04-10 2012-03-01 Fukuoka Univ ユビキチン融合遺伝子およびそれを用いたdnaワクチン
CN102770156B (zh) 2009-12-16 2016-01-20 克洛恩泰克制药股份公司 密码子优化的乙型肝炎病毒核心抗原(hbcag)
US9931387B2 (en) 2013-03-28 2018-04-03 Invectys Cancer vaccine for cats
DK2978444T3 (en) 2013-03-28 2019-03-18 Invectys CANCERVACCINE FOR DOGS
ES2771862T3 (es) 2013-10-28 2020-07-07 Invectys Una vacuna de ADN que codifica telomerasa
KR20160113158A (ko) * 2014-01-27 2016-09-28 몰레큘러 템플레이츠, 인코퍼레이션. 폴리펩티드를 전달하는 mhc 클래스 i 항원결정기

Also Published As

Publication number Publication date
EP3062824B1 (en) 2019-11-27
CY1122839T1 (el) 2021-10-29
NZ719098A (en) 2022-08-26
EA201690884A1 (ru) 2016-11-30
JP6545162B2 (ja) 2019-07-17
AU2014343813A1 (en) 2016-05-19
IL245186B (en) 2021-02-28
ES2771862T3 (es) 2020-07-07
CA2927702C (en) 2022-06-07
IL245186A0 (en) 2016-06-30
PT3062824T (pt) 2020-02-21
BR112016009002A2 (pt) 2017-10-03
EP3666290A1 (en) 2020-06-17
US12064474B2 (en) 2024-08-20
DK3062824T3 (da) 2020-02-17
JP2017502649A (ja) 2017-01-26
EA034928B1 (ru) 2020-04-08
KR20160111362A (ko) 2016-09-26
EP3062824A1 (en) 2016-09-07
HK1225986A1 (en) 2017-09-22
HRP20200211T1 (hr) 2020-05-15
KR102252756B1 (ko) 2021-05-17
US20190000946A1 (en) 2019-01-03
CA2927702A1 (en) 2015-05-07
US20160263204A1 (en) 2016-09-15
BR112016009002B1 (pt) 2023-05-02
ZA201603452B (en) 2020-08-26
RS60232B1 (sr) 2020-06-30
CN106061509A (zh) 2016-10-26
CN106061509B (zh) 2022-04-08
MX2016005389A (es) 2016-08-03
WO2015063117A1 (en) 2015-05-07
PL3062824T3 (pl) 2020-06-15
SI3062824T1 (sl) 2020-04-30
HUE047898T2 (hu) 2020-05-28
AU2014343813B2 (en) 2020-02-27
MX372778B (es) 2020-06-29
SG11201603118TA (en) 2016-05-30
US10183065B2 (en) 2019-01-22

Similar Documents

Publication Publication Date Title
FR3006466B3 (fr) .
BR302014001376S1 (pt) Configuração aplicada em bolsa.
LT3062824T (lt) Telomerazė, koduojanti dnr vakciną
LT3074534T (lt) Būdai, skirti polinukleotido sekoskaitai
HRP20181376T1 (hr) Poboljšana cjepiva protiv poksvirusa
DK2975030T3 (da) Dihydropyridazin-3,5-dion-derivat
EP2995028A4 (en) RECOVERY OF N-UPLETS
FR3001302B1 (fr) .
EP2796910C0 (de) Endkappe
CL2016001315A1 (es) Separador.
DK2958935T3 (da) Vaccine
EP2923944A4 (en) ornithopter
FR3001303B1 (fr) .
DE112014002244A5 (de) Infusionslösung
GB201315714D0 (en) DNA Construct
BR302013000239S1 (pt) Configuração aplicada em tamanco.
GB201306171D0 (en) Cawesway-coclaine, mod enhancers
UA27551S (uk) Пуф
GB201312935D0 (en) T,b,s
TH148359B (th) ไพรโรลิดีน-2-คาร์บอกซาไมด์ที่ถูกแทนที่
BR302013000594S1 (pt) Configuração aplicada em alça.
ES1086579Y (es) Vaso multiusos
BR302013006684S1 (pt) Configuração aplicada em garrafa.
BR302013000627S1 (pt) Configuração aplicada em grelha.
ES1134036Y (es) Sacacorchos